Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.

J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001. Epub 2009 Mar 10.

2.

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ.

J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.

3.

Individualized estimates of overdiagnosis in screen-detected prostate cancer.

Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R.

J Natl Cancer Inst. 2014 Feb;106(2):djt367. doi: 10.1093/jnci/djt367. Epub 2014 Jan 7.

4.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
5.

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ.

J Natl Cancer Inst. 2003 Jun 18;95(12):868-78.

PMID:
12813170
6.

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

Barry MJ, Mulley AJ Jr.

J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10. No abstract available.

PMID:
19276451
7.

Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ.

J Natl Cancer Inst. 2014 Dec 13;107(1):366. doi: 10.1093/jnci/dju366. Print 2015 Jan.

8.

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.

Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R.

J Clin Epidemiol. 2011 Dec;64(12):1412-7. doi: 10.1016/j.jclinepi.2011.06.011.

9.

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Welch HG, Albertsen PC.

J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. doi: 10.1093/jnci/djp278. Epub 2009 Aug 31.

10.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H.

BMC Med. 2014 Feb 11;12:26. doi: 10.1186/1741-7015-12-26.

11.

Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial.

Xia J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R.

J Natl Cancer Inst. 2013 Apr 17;105(8):546-50. doi: 10.1093/jnci/djt017. Epub 2013 Feb 14.

12.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
13.

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Gulati R, Gore JL, Etzioni R.

Ann Intern Med. 2013 Feb 5;158(3):145-53. doi: 10.7326/0003-4819-158-3-201302050-00003.

14.

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

Telesca D, Etzioni R, Gulati R.

Biometrics. 2008 Mar;64(1):10-9. Epub 2007 May 14.

PMID:
17501937
15.

Screening for prostate cancer in the US? Reduce the harms and keep the benefit.

de Carvalho TM, Heijnsdijk EA, de Koning HJ.

Int J Cancer. 2015 Apr 1;136(7):1600-7. doi: 10.1002/ijc.29136. Epub 2014 Sep 1.

16.
17.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
18.

Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.

van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH.

J Natl Cancer Inst. 2003 Oct 1;95(19):1462-6.

PMID:
14519752
19.

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.

PMID:
21601352
20.

Overdiagnosis and overtreatment of prostate cancer.

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9. Review.

Supplemental Content

Support Center